Clinical Trials

The PREVAIL Trial Shows That Enzalutamide Not Only Increases Overall Survival Over Placebo, It Also Delays the Onset Of The First Skeletal Event

Analysis of the PREVAIL Trial showed that Enzalutamide (Xtandi) significantly increased overall survival and radiographic progression-free survival compared with placebo in men with prostate cancer who were asymptomatic and minimally symptomatic, chemotherapy-naive and who had metastatic castration-resistant prostate cancer (mCRPC). Now, an additional analysis of the data has shown the effect enzalutamide also has on [...]

By Malecare|2020-02-04T11:37:24-05:00May 22nd, 2015|Advanced Prostate Cancer, Bones and Prostate Cancer, Clinical Trials, enzalutamide, Quality of Life, survival, Uncategorized, Xtandi|0 Comments

More People Surviving Cancer, But There Remains Groups That Have Not Had A Benefit

The good news is that many more people are surviving years after a cancer diagnosis. According to a new analysis the proportion of people surviving cancer is increasing through out the United States. The analysis showed that for both men and women aged 50 to 64 who were diagnosed between 2005 to 2009 with a [...]

By Malecare|2015-04-28T12:02:58-04:00April 28th, 2015|Advanced Prostate Cancer, Clinical Trials, Research, Uncategorized|0 Comments

Understanding How Personalized Medicine Is Developed By Way Of A Real Situation – Olaparib

It is common knowledge that men with metastatic castration-resistant prostate cancer (CRPC) don’t all have the same disease. There are many different types or flavors of prostate cancer. These differences are involved in the genetic structure of the cancer cell its self. Some prostate cancers have mutations in the DNA repair genes (genes whose job [...]

By Malecare|2021-04-29T10:07:31-04:00April 24th, 2015|Advanced Prostate Cancer, Clinical Trials, Drugs & Treatments, genetics, Inhibitors, olaparnib, PARP inhibitors, Research, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales|2 Comments

Updated Overall Survival Data from a Phase 3 Trial of Ipilimumab vs. Placebo in Men Post Chemotherapy Receiving Radiation Therapy – Still Needs Time

Presented in a poster at the recent European Society of Medical Oncologist (ESMO) there was a data update of the phase 3 clinical trial (CA184-043) which evaluated overall survival (OS) in men having radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. Initially, this trial did not meet its endpoint [...]

By Malecare|2015-04-14T10:41:35-04:00April 14th, 2015|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, immunotherapy, ipilimumab, Radiotherapy, survival, Uncategorized, vaccines|0 Comments

On The Horizon – Tasquinimod – Immunotherapy & An Anti-Angiogenic Agent

In my commitment to report “On the Horizon” treatments for advanced prostate cancer today I will discuss an investigational treatment known as Tasquinimod. It is an experimental treatment that is both an immunotherapy and anti-angiogenic agent (designed to prevent the development of blood vesicles which would feed a tumor allowing its growth). In phase 2 [...]

By Malecare|2020-02-04T11:45:03-05:00April 9th, 2015|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, On The Horizon, survival, Tasquinimod (TASQ), Uncategorized|1 Comment

Phase III Trial Comparing Orteronel (TAK-700) Plus Prednisone Against Placebo Plus Prednisone Fails

Reporting both negative clinical trial results is as important as reporting positive results. However, pharmaceutical companies often bury negative results. Fortunately (actually unfortunately because there were negative results) a Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed [...]

By Malecare|2020-02-04T11:36:51-05:00April 3rd, 2015|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, TAK700, Uncategorized|0 Comments

Controversy at ASCO GU: Conflicting Randomized Trials on Docetaxel Plus ADT for Hormone Sensitive Metastatic Prostate Cancer *

Last year after the ASCO meeting in Chicago I declared that there was one particular presentation of the CHAARTED trial that would be a game changer for the treatment of newly diagnosed men with very significant prostate cancer. The game changer was that men diagnosed with significant disease and who were still ADT naive (not [...]

By Malecare|2020-02-04T10:39:13-05:00April 1st, 2015|Advanced Prostate Cancer, ASCO, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, taxotere, Uncategorized, Understanding APC|0 Comments

Detecting Prostate Cancer Cells in Blood Can Give An Early Warning of Treatment Failure and Shorten Clinical Trials

There is more evidence that the blood test used to count the number of cells circulating in the blood and shed from prostate tumors (circulating tumor cells or CTCs) can indicate whether a treatment is working or not working. A major new study showed that the number of these circulating tumor cells in the blood [...]

By Malecare|2017-10-19T10:47:29-04:00March 27th, 2015|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, CTCs, General Information, On The Horizon, Uncategorized, Understanding APC, Zytiga|0 Comments

A Real Role for Immunotherapy in the Treatment of Advanced Prostate Cancer

Immunotherapy has a major and expanding role in the treatment of cancer, including advanced prostate cancer. Over time there have been a number of naysayers as the immunotherapy Provenge has played the role whipping boy by critics. The common criticism leveled at Provenge can be summed up simply, “It doesn’t work.” The plain truth is [...]

By Malecare|2017-10-19T10:47:29-04:00March 26th, 2015|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, immunotherapy, ipilimumab, Prostvac, Uncategorized, vaccines, Yervoy|3 Comments

Coming Back to Continue the Blog and New Data Disclosed on Enzalutamide at the Plenary Session at the 2015 European Association of Urology Congress

Before I get into the meat of today’s post about enzalutamide, I want to briefly make some personal comments about my absence from this blog. As I had mentioned I have been diagnosed with a fifth primary cancer, appendiceal cancer. It is a rare cancer, which required my having to remove my appendix, a piece [...]

By Malecare|2017-10-19T10:47:29-04:00March 24th, 2015|Advanced Prostate Cancer, Casodex, Clinical Trials, Clinical Trials, Drugs & Treatments, enzalutamide, Hormone Therapy, Uncategorized, Xtandi|0 Comments